Education
About Us
Working with TipRanks
Follow Us
Avenue Therapeutics Inc (ATXI)
OTHER OTC:ATXI
Total Valuation
Avenue Therapeutics has a market cap or net worth of $795.26K. The enterprise value is -$2.81M.
Market Cap$795.26K
Enterprise Value-$2.81M
Share Statistics
Avenue Therapeutics has 3,183,603 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,183,603
Owned by Insiders33.62%
Owned by Institutions5.75%
Financial Efficiency
Avenue Therapeutics’s return on equity (ROE) is -4.17 and return on invested capital (ROIC) is -607.92%.
Return on Equity (ROE)-4.17
Return on Assets (ROA)-4.36
Return on Invested Capital (ROIC)-607.92%
Return on Capital Employed (ROCE)-6.08
Revenue Per Employee0.00
Profits Per Employee-5.85M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Avenue Therapeutics is -2.22. Avenue Therapeutics’s PEG ratio is >-0.01.
PE Ratio-2.22
PS Ratio0.00
PB Ratio0.19
Price to Fair Value9.26
Price to FCF-0.10
Price to Operating Cash Flow-0.09
PEG Ratio>-0.01
Income Statement
In the last 12 months, Avenue Therapeutics had revenue of 0.00 and earned -11.65M in profits. Earnings per share was -0.90.
Revenue0.00
Gross Profit0.00
Operating Income-11.28M
Pretax Income-11.65M
Net Income-11.65M
EBITDA-11.28M
Earnings Per Share (EPS)-0.90
Cash Flow
In the last 12 months, operating cash flow was -7.09M and capital expenditures 0.00, giving a free cash flow of -7.09M billion.
Operating Cash Flow-7.09M
Free Cash Flow-7.09M
Free Cash Flow per Share-2.23
Dividends & Yields
Avenue Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change-92.80%
50-Day Moving Average0.27
200-Day Moving Average1.54
Relative Strength Index (RSI)49.98
Average Volume (3m)5.19K
Important Dates
Avenue Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Avenue Therapeutics as a current ratio of 3.27, with Debt / Equity ratio of 0.00%
Current Ratio3.27
Quick Ratio3.27
Debt to Market Cap0.00
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Avenue Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Avenue Therapeutics EV to EBITDA ratio is -2.07, with an EV/FCF ratio of -2.58.
EV to Sales0.00
EV to EBITDA-2.07
EV to Free Cash Flow-2.58
EV to Operating Cash Flow-2.58
Balance Sheet
Avenue Therapeutics has $3.50M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$3.50M billion.
Cash & Marketable Securities$3.50M
Total Debt$0.00
Net Cash-$3.50M
Net Cash Per Share-$1.10
Tangible Book Value Per Share$0.14
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Avenue Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast87.42%